P1100 (DAIDS ID 11801): A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-Vaccinated, HIV-Uninfected Infants Without Evidence of Tuberculosis

Study Status Study Restriction



What is P1100?

P1100/ AERAS-402 (Protocol Number: C-029-402) is a phase II, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected infants without evidence of tuberculosis.

Study Documents:

Documents for the study are Confidential, contact the Clinical Trials Specialist for access.

Sites where the study is implemented:

CRS ID Site Name City Country
No records returned.

Aeras enrolling sites include SATVI in South Africa, KEMRI in Kenya, and CISM in Mozambique.

Study contacts:

Clinical Trials Specialist: Kathleen George

Clinical Trials Specialist: Charlotte Perlowski


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.